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Abstract
Expression of FAM171B Protein in Mouse Brain Tissue
Name - Quan Tran
Degree – Master of Science in Biology
University - Minnesota State University Mankato MN56001
Year - 2017
Polyglutamine (polyQ) diseases are inherited fatal neurodegenerative disorders
caused by expansion of trinucleotide cytosine-adenine-guanine (CAG) repeats, encoding
abnormally long glutamine tracts in respective disease proteins. Currently, there are nine
polyQ diseases- including Huntington’s disease and a number of Spinocerebellar ataxias.
Interestingly, expanded polyQ proteins are prone to aggregate, and this aggregation may
underlie neurodegeneration. In this study, we investigate the expression and localization
of FAM171B (a novel polyQ protein) in the brain. Western blotting reveals that
FAM171B protein is indeed expressed in the developing and adult mouse brain.
Furthermore, immunohistochemical analyses suggests widespread localization of
FAM171B to many brain regions - with pronounced expression in the hippocampus,
cerebellar Purkinje cells, and cerebral cortex. As a novel polyQ protein that is expressed
in the brain, our observations suggest that FAM171B can be considered a candidate gene
for as yet molecularly uncharacterized neurodegenerative diseases.
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Introduction
A large number of severe neurodegenerative diseases, including: Huntington’s
disease (HD), spinal-bulbar muscular atrophy (SBMA), several spinocerebellar ataxias
(SCAs) and Dentatorubral-Pallidoluysian atrophy (DRPLA), result from an expansion
mutation of a trinucleotide cytosine-adenine-guanine (CAG) repeat in the human genome
(Table 1).
Table 1. Summary of Polyglutamine diseases (Hueng, 2014).
Disease

Pattern of
Inheritance

Spinobulbar
X-linked recessive
Muscular
Atrophy
Huntington
Autosomal
disease
dominant
Dentatorubral
Autosomal
Pallidoluysian
dominant
Atrophy
Spinocerebellar
Autosomal
ataxia type 1
dominant
Spinocerebellar
Autosomal
ataxia type 2
dominant
Spinocerebellar
Autosomal
ataxia type 3
dominant

Normal
Repeat
length
9-36

Disease
Repeat
length
36-62

6-35

36-121

3-38

49-88

6-39

41-83

14-32

34-77

12-40

62-86

Spinocerebellar
ataxia type 6

Autosomal
dominant

4-18

21-30

Spinocerebellar
ataxia type 7
Spinocerebellar
ataxia type 17

Autosomal
dominant
Autosomal
dominant

7-18

38-200

25-43

45-63

Affected Brain
Region
Anterior horn, bulbar
neurons and dorsal
root ganglia
Striatum and
cerebral cortex
Cerebellum, cerebral
cortex and basal
ganglia
Cerebellar, Purkinje
cells brain stem
Cerebellar, Purkinje
cells brain stem
Cerebellar dentate
neurons, basal
ganglia and brain
stem
Cerebellar Purkinje
cells dentate nucleus
and inferior olive
Cerebellum, brain
stem
Cerebellar, Purkinje
cells, inferior olive
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As CAG encodes for the amino acid glutamine (Q), aberrant proteins containing polyQ
stretches that expand beyond their normal polymorphic range cause the above diseases,
which are referred to collectively as polyQ diseases (Zoghbi and Orr 2000).
CAG triplet repeat expansion mutation was first described in 1991 as a mutation
in the androgen receptor gene causing the progressive motor neuron disease SBMA (La
Spada et al., 1991). Since then, eight other diseases have also been described as being
derived from a CAG repeat expansion that passes beyond a specific length threshold.
PolyQ diseases are inherited in an autosomal dominant fashion, with the exception of
spinobulbar muscular atrophy, and typically are quite rare (Margulis, 2013). Of the polyQ
diseases, HD and SCA3 have the highest prevalence rates affecting ~1:10,000 individuals
worldwide (Margulis, 2013) and (Bauer, 2013). Although polyQ diseases are rare, they
are devastating to affected individuals as well as their families. To date, polyQ disease
therapy remains a significant challenge (Xia, 2004). Therefore, understanding both polyQ
pathogenesis and the normal molecular function of wild-type polyQ proteins within cells
may help find treatments or even cures for polyQ disease.
The pathological hallmark of polyQ disease is the accumulation of intracellular
inclusions or aggregates in widespread central nervous system and peripheral tissues
(Bradford, 2010). Interestingly, each disease pathology is largely restricted to specific
brain areas (Table 1) (Sharp et al., 1995). Intranuclear inclusions are commonly found in
degenerating neurons of the cerebral cortex, cerebellar Purkinje cells, cerebellum, brain
stem and spinal tract (Zoghbi, 1999).
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Numerous studies of affected neurons reveal that polyQ toxicity is likely due to
the ability of expanded polyQ peptides to form these inclusions (Ross and Poirer, 2004).
Indeed, aggregate formation likely explains the “toxic gain-of-function” that occurs with
expanded polyQ tracts. Misfolded and aggregated mutant polyQ proteins may affect
global cellular gene expression profiles, disrupt nuclear organization, or inhibit
proteasomal function (Williams and Paulson, 2008; Hueng, 2014, Goellner and
Rechsteiner 2003). Although numerous studies have shown that mutant polyQ proteins
form insoluble inclusions, there is no definitive agreement as to whether neuronal
aggregates play an essential role in pathogenesis. Indeed, some studies even suggest that
expanded polyQ protein aggregates may actually protect from cytotoxicity (Paulson et
al., 1997; Haacke et al., 2006; Saudou, 1998; Huynh, 2000; Tarlac, 2007).
Significant evidence from both cellular and animal models suggests that peptide
fragments of the expanded polyQ protein may actually be more toxic than their fulllength counterparts (Duennwald et al., 2006; Ikeda et al., 1996). For example, when a
fragment of mutant ataxin-3 was expressed in a mouse model of SCA3, the fragment
induced apoptotic cell death more rapidly than mice expressing the full-length mutant
ataxin-3 (Ikeda et al., 1996). Thus, protein fragments containing expanded polyQ tracts
seem to be more toxic than full-length proteins, and this may be a clue regarding the
pathogenic process.
Interestingly, a number of expanded polyQ proteins seem to localize to the
nucleus where they may abnormally interact with transcription factors to affect gene
expression profiles. For example, Yoo et al. (2003) demonstrated that expanded CAG
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repeats introduced into the mouse sca7 gene resulted in substantial disruption of
photoreceptor gene expression. In another study, mutant ataxin-1 was found to interact
with PQBP-1, and this association was linked to decreased transcriptional levels in
Spinocerebellar type I (Komuro et al., 1999). Studies in Huntington’s disease have also
revealed that expanded polyQ tracts interfere with CBP-activated gene expression, and
over expression of CBP rescues polyQ toxicity (Nucifora et al., 2001). Thus, numerous
studies have linked expanded polyQ tracts to gene expression dysregulation. However,
the precise mechanisms leading to downstream neuronal cell death are not entirely clear.
One feature common to the majority of polyQ disease is late onset. In affected
individuals, polyQ diseases typically manifest in the fourth and fifth decade of life.
Interestingly, however, the precise age of onset and severity of disease is dependent upon
the severity of CAG repeat tract expansion. Normal alleles of polyQ disease linked genes
are typically polymorphic- containing between 10-30 CAG repeats (Table 1), while
mutant alleles contain 40-100’s of repeats (Agnieszka and Wlodzimierz, 2014).
Interestingly, there seems to be a strong correlation between disease severity and mutant
repeat tract length. In general, the longer the mutant repeat tract the earlier and more
severely each disease manifests in afflicted individuals (Walker, 2007). Furthermore,
disease symptoms often appear earlier in subsequent generations within affected polyQ
families. This phenomenon of genetic anticipation can be molecularly explained by the
increased genetic instability that accompanies increased CAG tract length. In other
words, when a CAG repeat tract becomes long enough to cause disease, it also somehow
becomes prone to more frequent DNA expansion mutations (Gacy et al., 1995, Kovtun et
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al., 2001). In general, repeat tract length changes likely occur during meiosis, and are
often greater in spermatogenesis than oogenesis (La Spada et al., 1992).
The mechanism underlying the abnormal expansion of polyQ stretches remains
largely unknown. However, formation of alternative DNA structures (such as hairpins)
during meiotic replication may be fundamental to this form of genetic instability (Gacy et
al., 1995, Kovtun et al., 2001). Indeed, the propensity for triplet repeat expansion
mutation likely depends upon several factors including length of the initial triplet tract,
the ability to form alternative DNA structures, and the effect of modifying genes (Zühlke,
1993, McMurray 2010).
One candidate set of modifying genes include DNA mismatch repair (MMR)
enzymes. Studies have shown that, unlike hereditary forms of colon cancer, DNA
mismatch repair enzymes themselves are not mutant in polyQ disease (Goellner et al.,
1997). Instead, the evidence suggests that normal DNA repair machinery is “hijacked” by
expanded triplet repeat tracts (perhaps by alternative DNA structure formation), and
while trying to fix this DNA structural abnormality repair enzymes may instead actually
contribute to the mutation (Manley et al., 1999; Kovtun and McMurray, 2001). In support
of this idea, when HD transgenic mice were crossed with mice lacking MSH2, triplet
repeat expansion in germ cells and somatic tissue was abolished (Manley et al. 1999).
These results suggest that MSH2 mismatch repair enzymes are somehow involved in
expansion mutation, and it is likely that alternative DNA structure formation by the triplet
repeats is recruiting repair enzymes to the process (McMurray, 2008).
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Despite polyQ diseases sharing similar mutation and clinical features, the diseases
are a complex group of disorders. Studies on proteins containing polyQ expansions
continue to progress and advance, and finding better treatment options for polyQ disease
remains paramount. The vast body of knowledge already contributed to polyQ disease
research opens up new challenges and opportunities for greater understanding of polyQ
disease. Similarly, discovery of novel proteins containing polyQ repeats with the
potential to undergo expansion mutation may shed light on genetically uncharacterized
neurodegenerative diseases, and elucidate the field in general.
In this regard, the sequencing of the human genome has revealed a number of
completely novel proteins containing polyQ repeats that have yet to be molecularly
characterized. Using the bioinformatic algorithm BLAST, our lab has recently identified
one such protein FAM171B; a novel polyQ protein with approximately fourteen
consecutive glutamines in its reported primary amino acid sequence (The UniProt
Consortium, 2017). Further analysis reveals that FAM171B is located on chromosome
2.q31, and there are likely eight exons that can be transcribed into two predicted
alternative mRNA splice forms encoding proteins of 92kDa and 48kDa respectively (The
UniProt Consortium, 2017). Bioinformatic analysis suggests that FAM171B may also
have various posttranslational modifications (Ex. Glycosylation) that ultimately affect its
structure and function (Table 2).
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Table 2. Amino acid modifications. Summary of putative posttranslational modification
from human and mouse (The UniProt Consortium, 2017).
Feature Key

Position (s)

Description

Glycosylation (Human)

108

N-linked (GlcNac..) Asparagine

Glycosylation (Human)

113

N-linked (GlcNac..) Asparagine

Glycosylation (Human)

213

N-linked (GlcNac..) Asparagine

Glycosylation (Human)

268

N-linked (GlcNac..) Asparagine

Modified residue (Human)

794

Phosphoserine

Glycosylation (Mouse)

109

N-linked (GlcNac..) Asparagine

Glycosylation (Mouse)

114

N-linked (GlcNac..) Asparagine

Glycosylation (Mouse)

214

N-linked (GlcNac..) Asparagine

Modified residue (Mouse)

792

Phosphoserine

As a completely uncharacterized protein, FAM171B expression levels, tissue
localization, and specific cellular functions have yet to be determined.
In this study, we perform both immunoblot and immunohistochemical assays to
analyze FAM171B expression and localization within the mouse brain. Our results
corroborate previous studies from our lab (that used in-situ hybridization), and strongly
suggest that FAM171B is widely expressed throughout the brain with pronounced
expression in cells of the hippocampus, cortex, and cerebellum. As we find that
FAM171B is indeed expressed in the brain, this novel protein should be considered a
candidate gene for as yet molecularly uncharacterized neurodegenerative diseases.
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Materials and methods
Animals: C57BL/6 male mouse (IACUC 15-02) were maintained in
12.88x7.50x5.63 inch cages. Trained animal care staff provided daily monitoring of the
mice. A 12:12-hour light and dark cycle was provided (0800:2000), and temperature was
maintained within standard guidelines. Mice received water and certified laboratory diet
(Rodent Diet, LabDiet), and were transferred to cages with clean bedding once every
week. Date at which pups were born was recorded, and mice were maintained as above
until they were of appropriate research age.
Mouse brain dissection: Male mice brains were dissected at postnatal days seven
(P7), twenty-one (P21), and forty-two (P42), as well as six months (6M) and snap frozen
by placing on dry ice. For specific brain regions study, certain brain regions (including:
hippocampus, cortex, cerebellum, brain stem, and thalamus) were first isolated prior to
freezing. To isolate different regions, a freshly collected brain was place on an ice-chilled
slide and bisected along the midline with a razor blade. A coronal cut was made at the
lower back of the brain to remove the cerebellum and brain stem. Next two spatulas were
used to separate the cerebellum from the brain stem. A mid-sagittal cut was then made
before left and right hippocampal regions were isolated; one spatula was anchored over
the cortex, at the same time the other spatula tip was placed near the junction to allow the
thalamus region to be peeled away exposing the hippocampus. While anchoring the brain
with one spatula tip, the other was placed just under the caudal tip of the hippocampus
and carefully applied pressure was directed to the medial white matter tracts with the
anchoring spatula while moving the second spatula tip anteriorly and posteriorly. Once
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the thalamus and hippocampus was removed, the remaining tissue was considered cortex.
Isolated brain regions were snap frozen on dry ice and stored at – 80oC for later use.
Preparation of mouse brain lysate: Whole mouse brains (and isolated brain
regions described above) were weighed, thawed, and diced into fine pieces with a razor
blade prior to being transferred to a microcentrifuge tube containing ice-cold 2X RIPA
lysis buffer (10mM Tris pH 7.5, 300mM NaCl, 2% Nonidet P-40, 1% Na-Deoxycholate,
protease inhibitor cocktail). For every one-gram of mouse brain tissue, 3ml ice-cold
RIPA lysis buffer was added. Next, the mouse brain tissue solution was vigorously
vortexed until homogenous, and the solution was incubated on ice for 30 minutes with
occasional vortexing. Brain tissues debris was removed by microcentrifugation for 20
minutes at 18,000xg in 4oC. The supernatant was aliquoted into a fresh microfuge tube,
and incubated on ice prior to protein concentration determination via a Bradford assay.
Bradford assay for protein concentration: 20µl of brain lysate diluted in double
deionized water (1:50, 1:100) was added to a cuvette containing 1ml Bradford reagent.
The mixture was incubated for 10 minutes prior to analysis by using a spectrophotometer
(nanodrop2000, Thermofisher) at 595nm absorbance. Once protein concentration was
determined, an equal amount of brain lysate and 2X SDS loading buffer (1.0M Tris/HCL
pH 6.8, 20% SDS, 50% Glycerol, 0.16M Dithiothreitol, 0.2mg/ml Bromophenol blue)
were mixed together in a microcentrifuge tube and stored at -20oC.
Western Blot: Electrophoreses of the mouse brain lysates was performed to assay
for the presence of FAM171B. Briefly, 5µl molecular weight ladder (928-4000, Odyssey)
and 100µg of total protein from P7, P21, P42, and 6M (as well as brain regions described
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above) were loaded onto 8% SDS/PAGE gels. Electrophoreses was performed at 100
volts for 1 hour in running buffer (25mM Tris-base, 192mM Glycine, 3.5mM SDS) Next,
proteins were transferred onto a nitrocellulose membrane in order to probe for
FAM171B. A wet transfer system (Biorad) was utilized, and the chamber was filled with
transfer buffer (2.5mM Tris-base, 19.2mM Glycine, 10%MeOH) The transfer was
allowed to run over night at 100mA.
Immunoblot analysis of FAM171B protein: Nitrocellulose membranes containing
mouse brain proteins were blocked in 3ml phosphate buffer solution (PBS) (Odyssey,
Licor) for 3 hours at room temperature. Next, the nitrocellulose membranes were probed
with 3ml primary Ab (1:1000, NBP1-93847, Novus Biological) diluted in PBS buffer,
and incubated overnight at 4oC. The next day, membranes were washed in Tris-buffered
saline Tween (TBS-T) (25mM Tris-base, 150mM NaCl, 0.1% Tween20, pH 7.4) five
times each time for five minutes. Next, 3ml of secondary antibodies (1:10,000 Goat-antiRabbit-IRdye680LT, Odyssey, Licor) diluted in PBS block buffer was added to the
membranes and incubated overnight at 4oC. The following day, membranes were washed
five times in TBS-T (each time for five minutes) before imaging on a Li-COR Odyssey in
the 700nm channel. Lastly, the immunoblot photographs were converted into gray scale
and inverted using Adobe Photoshop.
Peptide Block Negative Control FAM171B Immunoblots: In order to verify
primary Ab specificity, “peptide block” control experiments were performed. Briefly, the
peptide that the Novus Ab was raised against (NBP1-93847PEP, Novus) was diluted into
PBS blocking solution to yield (0.1µg/µl). In a different tube, primary Ab was diluted
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(1:1000) in PBS blocking buffer, and divided into two identical aliquots. One aliquot
remained unchallenged while the other received peptide (at a 2:1 molar ratio of peptide to
Ab), and both antibody solutions were incubated overnight at 40C. The next day, both
aliquots were centrifuged for 15 min at 15,000xg to pellet any immune complexes. The
supernatant was then pipetted into a fresh tube to be used as an immunoblot working
solution.
FAM171B Positive Control Immunoblots: HEK-293 cell lines transfected with
FAM171B-GFP were used as a positive control for Ab specificity. Briefly, HEK cells
were subcultured into six-well plates containing 2ml DMEM/well (Thermoscientific)
culture media supplemented with 10% fetal bovine serum. Cells were allowed to attach
and grow at 37oC overnight. The next day, media from cells to be transfected was
replaced with 2mL of serum free medium Opti-MEM I (GIBCO) (untransfected cells
remained in original media). Cells were transfected with 500ul Opti-MEM I
supplemented with 10µL lipofectamine 2000 (Invitrogen) and 5µg FAM171B- GFP
plasmid. Transfection was allowed to continue at 37oC for 4-5 hours, after which the
transfection media was replaced with 2ml DMEM/Serum and the cells were incubated
overnight at 370C. Both untransfected and transfected HEK cells were lysed with 250ml
of 2X RIPA buffer/well (supplemented with protease inhibitor cocktail) and cell extracts
were collected for protein concentration as above.
Immunoblot quantification of FAM171B. Immunoreactive bands were analyzed
by image studio (version 3.1). All immunoreactive bands present in each lane were
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measured for total protein quantification. In addition, predominant bands were measure
independently, by manually selecting each band across all ages.
Immunohistochemistry tissue processing and preservation: Sagittal sections of the
left hemisphere were cryo-sectioned at 20µm and collected onto “super frost charged”
glass slides (Thermofisher). Briefly, we discarded the initial 200µm of brain tissue and
collected the next 20µm tissue section onto the slide. Then, we discarded the next 100µm
brain tissue before collecting the next 20µm section. Collected sections used for controls
were adjacent to that of the experimental tissue. We repeated the above steps throughout
the entire left-brain, and tissue sections were stored at -80oC until IHC was performed.
Immunohistochemical procedure for frozen sections: Immunohistochemistry
(IHC) was performed on frozen brain tissue as follows. Slides containing frozen sections
were thawed at room temperature for 15 minutes, and then incubated in ice-cold 0.75%
H2O2/methanol for 30 minutes to block endogenous peroxidase activity. After 30
minutes, excess fluid on the slides was tapped off on a paper towel before washing the
slides with vectastain buffer (10mM Na2PO4, 0.9% saline (PBS), pH 7.5). Next, a
blocking pen was used to mark the perimeter, and 300µl vectastain block serum
(Vectastain ABC kit) was pipetted onto the slides. Slides were incubated in block serum
for 2 hours at room temperature. After 2 hours, block serum was removed and 300µl of
primary Ab (Rabbit anti-FAM171B, Novus) diluted 1:500 in vectastain block serum was
pipetted onto the slides, and incubated at 40C overnight. Following overnight incubation,
slides were washed five times (5 min each time) with vectastain buffer. Then 300µl of
secondary Ab (Goat-anti-rabbit, Vectastain ABC kit) diluted 1:10,000 in vectastain block
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serum was applied to each slide for 90 minutes at room temperature. Next, slides were
washed as above prior to incubation in 300µl of ABC Vectastain reagent (Vectastain
ABC kit) for 45 minutes. After 45 minutes, the slides were again washed five times (5
min each time) with vectastain buffer. DAB solution was then pipetted onto each slide
and allowed to incubate for ~20 seconds before the slides were submersed in distilled
water to stop the colorimetric reaction. Finally, slides were cover-slipped using aquapolymount (Polyscience Inc.).
The same IHC procedure was utilized on control sections, except that the negative
control sections never received primary Ab, but instead remained in vectastain block
serum. Additionally, slides were exposed to a peptide block at a molar ratio of 15:1,
where the primary Ab (1:500) was incubated with peptide specific for the antibody in
PBS overnight at 40C before being applied to slides. Buffer used for Ab incubations was
also changed to PBS.
Photography: We photographed brain profiles from thin DAB stained sections
using optical microscope (Zeiss) with a progress C10 Plus camera (Jenoptic) connected to
a computer. Photographs were taken with various objectives including: 5X (EC PlanNeofluor, Zeiss), 40X (EC Plan-Neofluor, Zeiss), and 100X 1.25 oil (Anchroplan).
Sections lengths were measured with a reticule that is divided into 0.1mm and the last
0.2mm is divided into units of 0.01mm (Krabbenhoft). Whole brain cross sections were
measured using a ruler (Fine science tools), with a scale of 1mm.
Qualitative analysis: FAM171B immunostain levels (hippocampus, cerebellum,
cortex, amygdala, thalamus, caudate and corpus callosum) was observed using a
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compound light microscope. Relative immunostain intensity was assigned as follows:
high signal (+++), medium signal (++), low signal (+), and no signal (-).
Statistical analysis: Statistically significant differences between age groups was
determined by univariate ANOVA analyses using IBM SPSS statistics. All analyses
measured FAM171B expression across all ages (N=3). Standard errors were calculated
by using Microsoft excel.
Results
Immunoblotting of adult mouse brain extracts reveals two predominant bands at
approximately 92 kDa and 48kDa, matching well the predicted molecular weights for the
two FAM171B mRNA spliceforms (Figure 1). These results strongly suggest that
FAM171B is indeed expressed in mouse brain.

Figure 1. FAM171B protein is expressed in adult mouse whole brain. Blue arrows
show both FAM171B splice forms detected at 92kDa and 48kDa from adult mouse brain
extract. The primary Ab was diluted (1:100).
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However, to ensure the primary Ab bound specifically to FAM171B (but not
other proteins in the brain) we performed both negative and positive controls. In the
negative control (peptide block), the primary Ab was pre-incubated in peptide prior to
probing for FAM171B. Incubating the primary Ab in the peptide ensures the primary Abbinding sites are blocked. Hence, completely blocked primary Ab should not yield bands
at the predicted molecular weights. Our results strongly suggest that our primary Ab
(Novus) does not significantly detect proteins other than FAM171B in mouse brain
(Figure 2B). Furthermore, we performed positive control experiments using human
embryonic kidney (HEK-293) cell lines transfected with a FAM171B-green fluorescence
protein (GFP) fusion protein. HEK cells expressing FAM171B-GFP should yield a band
of ~120 kDa, and indeed we observed a strong immunostain at this predicted molecular
weight (Figure 2C). Together, negative and positive control experiments strongly suggest
that the Novus primary Ab recognizes FAM171B and is quite specific.
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Figure 2. FAM171B negative and positive control. Immunoblots show the position of
the molecular weight markers (kDa) indicated in the left. The experimental blot indicates
the predominant isoform being the 48kDa (A). The peptide block did not show any crossreactivity of antibody to proteins other than FAM171B (B). HEK transfected with
FAM171B-GFP indicate a dominant band at the predicted molecular weight of 120kDa,
not detected in the untransfected lane (C). The primary Ab diluted (1:1000).
With confidence in our primary Ab, we investigated the expression of FAM171B
in mouse brains across all age groups used in our study. Our results reveal that FAM171B
is expressed throughout post-natal development, with predominant isoforms of 92kDa
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and 48kDa (Figure 3). Interestingly, however, the immunoreactive intensity of the 92kDa
isoform decreased significantly from P7 to 6M. In contrast, the 48kDa isoform remained
constant throughout all ages (Figure 3). Furthermore, the Ab labeled an additional band
~75 kDa in P7 that disappeared in adult mice.

Figure 3. FAM171B is expressed in mouse whole brain across all ages.
Immunoreactive bands were detected at 92kDa and 48kDa from postnatal 7, 21, 42-day,
and 6-month.
We also quantified the level of FAM171B protein in each age group.
Immunoreactive bands on the western blots were analyzed by IBM SPSS statistics, and
univariate ANOVA was used to determine statistical differences between age groups
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(Figure 4A). In addition, individual splice-forms were analyzed (Figure 4B). Although
our results show a gradual decrease in FAM171B expression as mice become adults, this
trend did not reach significance.

Figure 4. FAM171B age quantification. The level of FAM171B expression was highest
in P7 and gradually decreased as mice became adults. Panel A shows level of protein
expression from the 48kDa isoform (N=3) with univariate ANOVA analysis (F3,12=2.47,
P=0.137). Panel B shows univariate ANOVA analysis of the 75 kDa isoform (F3,12=2.96,
P=0.098). Panel C shows univariate ANOVA analysis of the 92 kDa isoform (F3,12=3.01,
P=0.095).
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Furthermore, using western blotting we also examined individual brain regions
for FAM171B protein expression. Various brain regions were isolated, and each
individual region was probed for FAM171B expression (Figure 5). Results from these
biochemical assays suggest that FAM171B is widely expressed throughout the brain,
with the predominant splice-form being the 48kD species.

Figure 5. FAM171B expression in different mouse brain regions. Fractionated brain
regions were probed for FAM171B, and immunoreactive bands were detected at 92kDa
and 48kDa throughout the brain.
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To further establish where FAM171B protein localizes within mouse brain,
immunohistochemical assays were also performed. These studies clearly indicate the
presence of FAM171B protein in many regions of mouse brain (Figure 6), and
corroborate nicely our biochemical assays.

Figure 6. Whole brain section. IHC sections were photographed by dissecting
microscope. Cells expressing FAM171B are stained brown. Magnification 10x.
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Furthermore, these data complement nicely FAM171B mRNA expression distribution
found in previous in situ hybridization studies (Figure 7).
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Figure 7. FAM171B expression using different assays. Widespread expression of
FAM171B in the whole brain was observed using three different techniques.
Microphotograph from in-situ hybridization and immunohistochemical analyses showed
FAM171B widely expressed throughout the brain (A and B). Immunoblot analysis also
shows FAM171B is expressed throughout the brain (C).
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Such widespread expression of FAM171B from the whole brain sections raised
concern whether the brown stain observed for FAM171B is a false positive as result from
secondary Ab binding to tissue sections. Therefore, negative control experiments
(without primary Ab) were performed to eliminate the possibility of nonspecific binding
(Figure 8). Our results strongly suggest that our secondary Ab did not bind directly to the
tissue.

Figure 8. Negative control without primary antibody. Microphotograph from three
major brain regions including the cerebellum, hippocampus, and cortex. Red arrows
indicate cells expressing FAM171B protein. Negative control sections, not exposed to
primary Ab, yield no stain.
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Furthermore, we also performed peptide block experiments where the primary
Ab-binding sites were blocked with peptide prior to IHC. As predicted, peptide block
sections did not display immunostain, although experimental sections also displayed a
modest decrease in staining (Figure 9).

Figure 9. Peptide block control. Microphotograph from three major brain regions
including the cerebellum, hippocampus, and cortex. Red arrows indicate cells expressing
FAM171B protein. Peptide block control sections yielded little immunostain.
Magnification 5x (Close up view in black box).
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FAM171B immunohistochemical staining was qualitatively analyzed by
observing the intensity and relative number of cells stained in each major brain region
(Table 3). We found widespread expression of FAM171B in many brain regions of mice.
Importantly, however, not all regions express it. For example, the corpus collosum white
matter tract does not express FAM171B (Figure 7, Table 3).
Table 3. Qualitative analysis of FAM171B expression. Brain regions of mice across all
ages were examined by light microscopy, and intensity of stain indicated by strong (+++),
moderate (++), little (+), and no staining (-).
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Although FAM171B is expressed throughout the brain, we were intrigued by the
pronounced expression in several specific brain regions including the hippocampus,
cerebellum and cortex. In the hippocampus, FAM171B immunostain was intense across
all ages (Figure 10).

Figure 10. FAM171B is expressed in the hippocampus across all ages. Significant
cellular stain was observed in both dentate gyrus and Ammons horn of the hippocampus.
Magnification 5x.
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Similarly, immunostain intensity was also strong in cells of the cortex throughout all age
groups (Figure 11).

Figure 11. FAM171B expression in the cerebral cortex across all ages. Red arrows
indicate cells expressing FAM171B protein. Magnification 40x.
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In contrast, the immunostaining decreased somewhat in the cerebellum as mice aged,
particularly in cerebellar molecular layer cells. Interestingly, similar findings were also
observed in previous in-situ hybridization experiments (Figure 12).

Figure 12. Molecular layer pattern in the Cerebellum. In-situ hybridization and IHC
microphotographs of the cerebellum. FAM171B expression patterns shown in red arrows.
Brown and purple color stain indicates FAM171B expression. FAM171B expression in
the granular layer and Purkinje cell layers remains robust.
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At a higher magnification, the staining from cerebellum of P7 appears different
compared to the other age groups. Specifically, the immunostain from P7 molecular layer
was much stronger than the other age groups. This phenomenon was also found using insitu hybridization (Figure 13).

Figure 13. Cerebellum layers of P7. In-situ hybridization and immunohistochemical
stains from Postnatal 7-day (P7). The brown and purple stain indicates FAM171B
expression. Red arrows point to different layers in the cerebellum. Stains are strong in all
three cerebellar layers of P7 mice.
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In addition, the pattern of cerebellar Purkinje’s cells in P7 was also different
compared to other age groups. In adult mice, the Purkinje’s cells were far apart from one
another, and lined up in a single row. In contrast, the Purkinje cells were close to one
another and somewhat disorganized in the cerebellum of P7 (Figure 14).

Figure 14 Purkinje cells of the cerebellum. Purkinje cells indicated by red arrows. The
Purkinje cells were neighboring to one another in postnatal 7 days. In contrast, the
Purkinje cells were spread out and form a single line in postnatal 42 and 6 months.
Magnification 40x.
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Lastly, the microphotographs reveal that the IHC stains were predominantly
spherical in shape with defined border. The stain was also deposited centrally in one area
of the cell, with less intense staining peripherally (Figure 15). However, where
FAM171B specifically localizes within cells cannot be confirmed in this study.

Figure 15 FAM171B expression in cortical cells. Red arrow indicates the immunostain
of cells expressing FAM171B protein. A strong oval-shaped immunostain predominates
in most cells. Magnification 40x.
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Discussion
FAM171B is an uncharacterized novel polyQ protein that contains fourteen
glutamine repeats in its reported primary amino acid sequence. Previous studies have
shown that abnormally long polyQ repeats in other proteins results in severe
neurodegeneration. Therefore, (if prone to expansion mutation) FAM171B might also be
eventually linked to polyQ disease. Previous studies in our lab using in-situ hybridization
suggest that FAM171B mRNA is widely expressed in the mouse brain. In this present
investigation, we performed both immunoblot and immunohistochemical (IHC) analyses
to confirm FAM171B protein presence and distribution in the brain. Our results strongly
suggest that FAM171B protein is indeed expressed in the brain, corroborating our
previous in-situ hybridization mRNA studies.
Western blotting of adult whole brain and isolated brain sub-regions show
specific and prominent bands near 48kD and 92kD- matching nicely the predicted
molecular weights of the two putative FAM171B mRNA splice forms (Figures 2,3). This
data strongly argues that FAM171B is robustly expressed in mouse brain. Interestingly,
immunoblot experiments do show immunoreactive bands near 75kDa in young mice that
diminish in intensity as the mouse matures (Figure 3). One possible explanation for this
occurrence is posttranslational processing events such as: proteolytic cleavage,
phosphorylation, or glycosylation that may affect migration status of FAM171B on
SDS/PAGE gels (see Table 2). An alternative explanation for the presence of “extra”
bands observed in the western blot of P7 mouse brain is the possibility of non-specific
binding of our primary antibody to a protein other than FAM171B. However, two pieces
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of evidence strongly argue that our primary Ab does specifically detect our target protein.
First, our positive control experiment (transfected FAM171B/GFP into HEK cells) shows
that our Ab is absolutely able to detect FAM171B; since there is very little banding in the
HEK alone lysate and a robust band near 120kD that matches the predicted molecular
weight of our FAM171B fusion protein (Figure 2). Second, our peptide block experiment
demonstrates that our primary Ab detects very little else besides the epitope it was raised
against (Figure 2). Thus, the overall data suggests that our Ab does specifically detect
FAM171B, and the presence of extra bands near 75kD in P7 mice is most likely due to
posttranslational processing events.
Our IHC analysis also suggests widespread expression of FAM171B in brain
(Figure 6). Furthermore, negative control (without primary Ab) experiments (Figure 8)
suggest endogenous cross reactivity was completely blocked and the secondary Ab did
not itself bind nonspecifically to the target tissue- giving a false positive signal. It is
unclear whether the immunostain we observe is exclusively neuronal or whether
FAM171B is also expressed in supporting glial cells. However, the strong immunostain
observed in cerebellar Purkinje cells suggests that FAM171B is clearly expressed in
certain neuronal populations (Figure 14). The most consistent and robust expression was
observed in the hippocampus, cerebellum, and cortex (Figure 8). Importantly, this
expression pattern matches nicely to our previous in situ hybridization results (Figures
7,12,13). Indeed, the combination of immunoblot, in situ hybridization, and IHC results
all lead to the conclusion that FAM171B is robustly and widely expressed in developing
and adult mouse brain.
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In the cerebellum, both immunohistochemical and in-situ hybridization assay
reveals a high level of FAM171B immunostain in postnatal 7-day that gradually
decreases in certain cell layers as mice become adults (Figure 12). Specifically, P7 mice
show intense immunostaining in the external granular layer (EGL), that diminishes in
older ages (Table 3; Figure 12). It is possible that FAM171B may be synthesized
differently at P7 as neurons continue to proliferate, differentiate, mature and migrate
during early developmental stages (Stiles, 2010). Interestingly, our western blot finding
of an “extra 75kDa band” correlates with this, and may help explain the immunostaining
observed in the cerebellar EGL in P7 mice that is lacking in older ages (Figure 12). In P7
mice, FAM171B might be involved in cellular processes that aid neuronal development,
and therefore specific alternative splice forms may be needed to accomplish such tasks.
In contrast, as the animals mature perhaps only the predominant FAM171B 92kDa and
48kDa splice forms are necessary to maintain adult neuron survival. Also, during early
brain development, neurons, glia, neuro-processes and synapses overproduced during
prenatal age decrease and sometimes migrate as the mice mature into adulthood (Stile,
2010). This also might help explain the decrease in cerebellar immunostain we observe,
particularly in the EGL, as mice develop into adults. As mice become adults, all forms of
FAM171B may simply be less significant to certain molecular layer cells.
Structurally, the cerebellum has three distinct regions including the molecular,
granular, and Purkinje cell layers. Of these layers, the molecular layer lies outermost.
This layer contains basket and stellate cells that tightly synapse with Purkinje cell
dendrites (Wang, 2002). Residing in the middle cerebellar layer are the Purkinje cells,
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with their extensive dendritic trees that branch profusely and make synaptic contact with
the molecular layer. Purkinje cells use GABA neurotransmitter to exert inhibitory effects
on their downstream targets. Finally, the innermost cerebellar layer contains numerous
granular cells that exert excitatory effects on their targets (Marr, 1969). Since it is
expressed early in development, our data suggests FAM171B may play a role during
formation of external granular layer cells. For example, FAM171B might help regulate
the expression of gene products that initiate synapse formation during early development.
Whether FAM171B serves as a transcription factor or transcription associated protein
remains to be determined.
Since a number of polyQ diseases affect the cerebellum (such as SCA1, SCA2,
SCA3, SCA6, SCA7), and FAM171B is significantly in this region of the brain
(including Purkinje cells) our data predict that expansion mutation of the FAM171B
polyQ tract may lead to a Spinocerebellar ataxia- like phenotype. Cerebellar diseases are
typically characterized by poor motor coordination. For example, overexpression of
mutant SCA3 decreased cerebellar Purkinje cell numbers resulting in severe cerebellar
atrophy and ataxia (Paulson et al., 1997). In this regard, it would be interesting to create a
similar transgenic mouse that expresses “expanded polyQ” lengths of FAM171B, and
observe for phenotypic characteristics described above.
Our results show that the cerebral cortex also robustly expresses FAM171B,
suggesting it may play a role in this region as well (Figure 11). The cerebral cortex is
considered the “central processor” of the brain because it is responsible for: language,
planning and organizing, as well as intelligence and personality determination (Bailey,
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2017). Structurally, the cortex is the outermost anterior brain region with abundant folds
called gyri. Folding allows for additional surface area and consequent increased brain
function capacity. The cerebral cortex contains a large number of neuronal and glial cell
bodies, as well as their dendritic and axonal projections (Kandel, 2000).
At the cellular and circuit level, the cerebral cortex is subdivided into various
functional areas including sensory, motor, and higher order cognitive regions. Therefore,
neuronal cell loss in the cortex may result in progressive deterioration of motor and
cognitive function. For example, prominent cell death occurs in the neostriatum and
cortex in adult onset HD (Francis, 2007). As a result, affected HD individuals show jerky
voluntary movements (chorea), irritability, depression and other mood alterations
(Harper, 1991). As the disease progresses the chorea movements become prominent, and
abilities such as walking, speaking, and swallowing progressively deteriorate (Thompson
et al., 1998). Based on its localization in brain, it may be predicted that expansion
mutation in FAM171B may also lead to similar phenotypes.
FAM171B is also expressed in the hippocampus of mice, suggesting that it may
normally function in memory formation- as the hippocampus plays a major role in this
regard (Columbo, 2000). Structurally, the hippocampus resembles a horseshoe shape, and
is a paired structure located on each side of the brain (Amaral, 2007). Damage to the
hippocampus significantly decreases the capacity to form new memories (Di Gennaro,
2006). Indeed, in vivo studies of long-term social memories demonstrate that the
hippocampus is significantly involved in memory consolidation and social recognition
(Matthies, 1989; van Wimersa Greidanus, 1996). Interestingly, in HD individual neuronal
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density significantly decreases in the CA1 area of the hippocampus resulting in memory
impairment (Spargo, 1993). Therefore, we predict that mice carrying mutant FAM171B,
(or perhaps even knockout mice) might be unable to consolidate memory or exhibit
cognitive impairment.
Although FAM171B’s cellular function in these areas remains unknown,
knowledge of basic neuroanatomy and from polyQ disease pathologies enable us to
predict roles in which FAM171B may play in these areas. However, to confirm function,
we would need to create and observe mice carrying either wildtype or mutant FAM171B
gene for clinical pathology signs and symptoms indicative of polyQ disease.
It will also be interesting to determine where FAM171B resides and functions
within cells. Aberrant polyQ proteins are found within various cellular compartments
(Table 1). For example, in spinal bulbar muscular atrophy androgen receptor (AR) polyQ
expansion results in neurodegeneration and SBMA (Simanainen et al., 2011). In the
cytoplasm, normal AR passes signals from androgens to target genes by interacting with
coregulatory proteins in the cytoplasm and specific response-elements in the DNA.
Androgens are important in the development and function of numerous tissues including:
skeletal muscle, bone marrow, hair follicles, male reproductive system, and brain
(Bagatell, 1996). Thus, mutations in the AR prevents androgen binding and proper
signaling of downstream gene expression. Indeed, partial to complete androgen
insensitivity and infertility result from AR mutation. (Gottlieb, 2001; De Bellis 1914).
Although our present study cannot determine whether FAM171B is exclusively
expressed in the nucleus, our data does show predominant oval-shaped immunostaining

38

with a well-defined border (Figure 15). Thus, FAM171B may function in neuronal
nuclei. However, further studies such as co-immunofluorescence coupled with confocal
microscopy will be required to definitively confirm intracellular localization of
FAM171B. Understanding intracellular localization of FAM171B will greatly aid us in
predicting its function within neurons. Additionally, protein- protein interaction studies
should shed light on FAM171B’s role in cellular processes. Indeed, these studies are
currently ongoing in our lab- using techniques such as immunofluorescence and coimmunoprecipitation.
As a novel polyQ protein that is expressed in the brain, our observations suggest
that FAM171B should be considered a candidate gene for as yet molecularly
uncharacterized neurodegenerative diseases. Further efforts in our lab include using
bioinformatic tools to search for diseases that map near the FAM171B locus (2q32.1). If
a disease gene is eventually linked near this chromosomal region, one could use PCR and
sequencing methodologies to assay FAM171B CAG repeat tract length in normal and
disease individuals. We would expect to find increased repeat tract lengths in affected
individuals only- if mutations in FAM171B cause the disease. It will be interesting to see
if FAM171B is ever linked to a disease in this way. Regardless, basic biological studies
of FAM171B (similar to these current experiments) will shed light on its normal function
within cells of the brain.

39

References:
1. Agnieszka F., and Wlodzimierz J.K. (2014). Oligonucleotide-based strategies to
combat polyglutamine diseases. Nucleic Acids Research 42:6787-6810.
2. Amaral, D, Lavenex, P. (2007). Hippocampal neuroanatomy. New York: Oxford
University Press. p. 37
3. Bagatell, C.J. and Bremner, W.J. (1996) . N.Engl.J.Med 334:707-714.
4. Bailey, R. (2017) Anatomy of the Brain- Cerebral Cortex. Thoughtco.
5. Bauer, P. O. and Nukina, N. (2009). The pathogenic mechanisms of polyglutamine
diseases and current therapeutic strategies. J. Neurochem. 110:1737–1765
6. Bradford, J.W., Li, S., and Li X.J. (2010) Polyglutamine toxicity in non-neuronal
cells. Cell Res. 20:400-407.
7. Colombo, M., Broadbent, N.. (2000). Is the avian hippocampus a functional
homologue of the mammalian hippocampus?. Neuroscience and Biobehavioral
Reviews. 24: 465–84.
8. De Bellis, A., Quigley, C. A., Marschke, K. B., El-Awady, M. K., Lane, M. V.,
Smith, E. P., French, F. S. (1994). Characterization of mutant androgen receptors
causing partial androgen insensitivity syndrome. The Journal of Clinical
Endocrinology & Metabolism, 78(3), 513–522.
9. Di Gennaro, G., Grammaldo, L.G., Quarato, P.P., Esposito, V., Mascia, A., Sparano,
A., Meldolesi, G.N., Picardi, A. (2006). Severe amnesia following bilateral medial
temporal lobe damage occurring on two distinct occasions. Neurological
Sciences. 27: 129–33
10. Duennwald, M. L., Jagadish, S., Muchowski, P. J., and Lindquist S. (2006). Flanking
sequences profoundly after polyglutamine toxicity in yeast. Proceedings of the
National Academy of Sciences of the USA 103: 11045–11050.
11. Francis O.W. (2007). Huntington’s disease. The lancet 369: 218-228.
12. Gacy, A.M., Goellner G.M., Juranic N., Macura S., and C.T. McMurray. (1995)
Trinucleotide Repeats That Expand in Human Disease Form Hairpin Structures In
Vitro. Cell. 81:533-540.

40

13. Goellner, G.M., Tester, D., Thibodeau, S.N., Almqvist, E., Goldberg, Y.P., Hayden,
M.R., and McMurray C.T. (1997) Different Mechanisms Underlie DNA Instability in
Huntington Disease and Colorectal Cancer. Am. J. Hum. Gen. 60:879-890.
14. Goellner, G.M. and M.C. Rechsteiner. (2003) Are Huntington’s and Polyglutamine
Based Ataxia’s Proteasomal Storage Diseases? Int. J. Biochem. Cell Biol. 35(5):56271. Review.
15. Gottlieb, B., Beitel, L. K., & Trifiro, M. A. (2001). Variable expressivity and
mutation databases: the androgen receptor gene mutations database. Human
Mutation, 17(5), 382–388.
16. Haacke, A., Broadley, S. A., Boteva, R., Tzvetkov, N., Hartl, F. U., and Breuer, P.
(2006). Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for
aggregation and sequestration of nonexpanded ataxin-3. Human Molecular Genetics
15: 555–568.
17. Harper P. S. (1991). Huntington's Disease. Philadelphia, PA: W. B. Saunders
18. Hueng-Chuen F., Li-Ing H., Ching-Shiang C., Shyi-Jou C., Giia-Sheun P., Tzu-Min
C., Shinn-Zong L.,and Horng-Jyh H. (2014). Polyglutamine (PolyQ) Diseases:
Genetics to Treatments Cell Transplantation 23: 441–458.
19. Huynh, D.P., Figueroa, K., Hoang, N. and Pulst, S.M. (2000). Nuclear localization or
inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in
mouse or human. Nat. Genet., 26, 44–50.
20. Ikeda, H., Yamaguchi, M., Sugai, S., Aze, Y., Narumiya, S., and Kakizuka A. (1996).
Expanded polyglutamine in theMachado-Joseph disease protein induces cell death in
vitro and in vivo. Nature Genetics 13:198–202.
21. Kandel, E. R., Schwartz, J. H., Jessell, T.M. (2000). Principles of Neural
Science (Fourth ed.). United State of America: McGraw-Hill p. 324
22. Kovtun, I.V., McMurray, C. (2001). Trinucleotide expansion in haploid germ cells by
gap repair, Nat. Genet. 27 407–411. DNA repair. 7: 1121-1134.
23. Kovtun IV, Goellner G.M., and C.T. McMurray. (2001) Structural features of
trinucleotide repeats associated with DNA expansion. Biochem Cell Biol. 79(3):32536. Review.
24. La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E. and Fischbeck, K.H.
(1991). Androgen receptor gene mutations in X-linked spinal and bulbar muscular

41

atrophy. Nature. 352: 77–79.
25. La Spada, A. R., Roling, D. B., Harding, A. E., Warner, C. L., Spiegel, R.,
Hausmanowa-Petrusewicz, I., ... & Fischbeck, K. H. (1992). Meiotic stability and
genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and
bulbar muscular atrophy. Nature genetics, 2: 301.
26. Manley, K., Shirley, T.L., Flaherty, L., Messer, A. (1999). MSH2 deficiency prevents
in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice.
Nat. Genet. 23: 471–473.
27. Margulis, B. A., Vigont, V., Lazarev, V. F., Kaznacheyeva, E. V., Guzhova, I. V.
(1997–2007). Pharmacological protein targets in polyglutamine diseases: Mutant
polypeptides and their interactors. FEBS Lett. 587 (13): 2013.
28. Marr, D. (1996). A theory of cerebellar cortex. Journal Physiol. Lond 202:437-470.
29. Matthies, H. (1989). In search of cellular mechanism of memory. Pro Neurobiol
32:277-349.
30. McMurray, C. (2008). Hijacking of the mismatch repair system to cause CAG
expansion and cell death in neurodegenerative disease. DNA Repair 7: 1121-1134.
31. McMurray, C.T. (2010) Mechanisms of trinucleotide repeat instability during
human development. Nature Reviews Genetics 11, 786–799.
32. Nguyen, D.F, Zhou, T., Shu, J., Mao, J-H. (2013). Quantifying chromogen intensity
in immunohistochemistry via reciprocal intensity. Cancer Incytes 2 issue 1
33. Nucifora Jr., F.C., Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M.,
Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L., et al. (2001). Interference by
huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular. 291:
2423-2428
34. Paulson, H. L., Perez, M. K, Trottier, Y., et al. (1997). Intranuclear inclusions of
expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19: 333–
344.
35. Ross, C.A. and Poirier, M.A. (2004). Protein aggregation and neurodegenerative
disease. Nat. Med. 10 (supply), S10–S17.

42

36. Saudou, F., Finkbeiner,S., Devys, D. and Greenberg, M.E. (1998). Huntingtin acts in
the nucleus to induce apoptosis but death does not correlate with the formation of
intranuclear inclusions. Cell 95: 55–66.
37. Sharp, A.H., Love, S.J., Schilling, G., Li, S.-H., Bao, J., Wagster, M.V., Kotzuk, J.A.
Steiner, J.P., Lo, A. et al. (1995). Widespread expression of Huntington’s disease
gene (IT15) protein product. Neuron 14:1065-1074.
38. Simanainen, U., Brogley, M. Gao, Y.R., Jimenez, M., Harwood, D.T., et al. (2011)
Length of the human androgen receptors glutamine tract determine androgen
sensitivity in vivo. Mol. Cell. Endocrinol 342:81-86.
39. Spargo, E., Everall, I. P., & Lantos, P. L. (1993). Neuronal loss in the hippocampus in
Huntington’s disease: a comparison with HIV infection. Journal of Neurology,
Neurosurgery, and Psychiatry, 56(5), 487.
40. Stiles, J., & Jernigan, T. L. (2010). The Basics of Brain Development.
Neuropsychology Review, 20(4), 327–348
41. Tarlac,V., Turnbull,V., Stefani,D., Kelly,L., Walsh,R. and Storey,E. (2007). Inclusion
formation by ataxins -1, -2, -3, and -7. Int. J. Neurosci., 117: 1289–1314.
42. The UniProt Consortium (2017). UniProt: the universal protein knowledgebase.
Nucleic Acids Res. 45: D158-D169
43. Thompson P. D., Berardelli A., Rothwell J. C., Day B. L., Dick J. P., Benecke R., et
al. (1988). The coexistence of bradykinesia and chorea in Huntington's disease and its
implications for theories of basal ganglia control of movement. Brain 111: 223-244
44. Van Wimersma Greidanus T.B, Maigret C. (1996). The role of limbicvasopressin and
oxytocin in social recognition. Brain Res 713:153–159.
45. Walker F.O. (2007) Huntington’s disease. Lancet 360:218-228
46. Wang, Y.; Gupta, A; Toledo-Rodriguez, M; Wu, C. Z.; Markram, H (2002).
"Anatomical, Physiological, Molecular and Circuit Properties of Nest Basket Cells in
the Developing Somatosensory Cortex". Cerebral Cortex. 12 (4): 395–410
47. Williams, A.J., and Paulson, H.L. (2006). Polyglutamine neurodegenerative disease
and regulation of transcription: assembling the puzzle. Genes Development 20:21832192.

43

48. Wood, E.R., Dudchenko P.A, Eichenbaum H. (1999). The global record of memory
in hippocampal neuronal activity. Nature 397:613-616.
49. Xia, H., Mao, Q., Eliason S.L., Harper, S.Q, Martins, I.H., Orr, H.T., Paulson, H.L.,
Yang, L., Kotin R.M., and Davidson, B.L. (2004). RNAi suppresses polyglutamineinduced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 8:816-820.
50. Yoo, S.Y., Pennesi, M.E., Weeber, E.J., Xu, B., Atkinson, R.,Chen, S., Armstrong,
D.L., Wu, S.M., Sweatt, J.D., and Zoghbi, H.Y. (2003) SCA7 knockin mice model
human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and
abnormalities in short-term plasticity. Neuron 37: 383–401.
51. Zoghbi, H. Y.; Orr, H. T. (1999). Polyglutamine diseases: Protein cleavage and
aggregation. Curr. Opin. Neurobiol. 9: 566–570
52. Zoghbi, H.Y. and Orr, H.T. (2000) Glutamine repeats and neurodegeneration. Ann.
Rev. Neurosci. 23: 217–247.
53. Zühlke, C., Rless, O., Bockel, B., Lange, H., & Thies, U. (1993). Mitotic stability and
meiotic variability of the (CAG) n repeat in the Huntington disease gene. Human
Molecular Genetics, 2(12), 2063–2067.

